A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

14% total revenue growth and 35% subscription revenue growth

Community care events to be held throughout summer at Curaleaf's Lehi, Provo, and Payson, Utah Medical Cannabis Pharmacies

Pharmacokinetic profile of oral transmucosal delivery of TH104 was comparable to intravenous delivery of reference drug

Positive safety/tolerability achieved with TH104 reporting a mild side-effect profile

Planning for Phase 2 trial for moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC) is ongoing and on track to initiate in 2024

New warehouses consolidate operations, expand storage capacity to enhance supply chain management and support e-commerce growth

mRNA-1083 met its primary endpoints, eliciting higher immune responses against influenza virus and SARS-CoV-2 than licensed flu and COVID vaccines in adults 50 years and older, including an enhanced influenza vaccine in adults 65 years and older

• Proxy related materials filed in relation to annual and special meeting of shareholders scheduled for June 27
• Audited annual financial statements expected to be completed this week
• Third advance of US$7 million under the Signing Loan with subsidiary of Hochschild Mining PLC ("Hochschild") to be received two business days following the satisfaction of all conditions precedent, including the issuance of financial statements